The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Valeant Pharmaceuticals International Inc

NYSE: VRX
Last

(U.S.) $15.46

Today's change+0.02 +0.13%
Updated December 9 4:00 PM EST. Delayed by at least 15 minutes.
 

Valeant Pharmaceuticals International Inc

NYSE: VRX
Last

(U.S.) $15.46

Today's change+0.02 +0.13%
Updated December 9 4:00 PM EST. Delayed by at least 15 minutes.

Valeant Pharmaceuticals International Inc up (U.S.)$0.02

Valeant Pharmaceuticals International Inc closed up Friday by (U.S.)$0.02 or 0.13% to (U.S.)$15.46. Although unchanged over the last five days, shares are down 84.79% for the last year to date. This security has underperformed the S&P 500 by 93.97% during the last year.

Key company metrics

  • Open(U.S.) $15.44
  • Previous close(U.S.) $15.44
  • High(U.S.) $15.89
  • Low(U.S.) $15.35
  • Bid / Ask-- / --
  • YTD % change-84.79%
  • Volume9,223,041
  • Average volume (10-day)13,191,186
  • Average volume (1-month)23,367,418
  • Average volume (3-month)22,067,792
  • 52-week range(U.S.) $13.77 to (U.S.) $119.87
  • Beta-0.13
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forward2.84×
  • Forward PEG0.23×
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$6.48
Updated December 9 4:00 PM EST. Delayed by at least 15 minutes.
S&P TSX0.11%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2016Q2/2016Q1/2016Q4/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015
Revenue2,4802,4202,3722,736
Total other revenue--------
Total revenue2,4802,4202,3722,736
Gross profit1,8221,7621,7422,060
Total cost of revenue658658630677
Total operating expense3,3432,3402,3052,542
Selling / general / administrative661672813743
Research & development10112410396
Depreciation / amortization807888695789
Interest expense (income), net operating--------
Unusual expense (income)1,1154442195
Other operating expenses, total1-452343
Operating income-8638166195
Interest income (expense), net non-operating-470-473-427-433
Gain (loss) on sale of assets--------
Other--------
Income before tax-1,332-377-366-240
Income after tax-1,219-304-373-362
Income tax, total-113-737122
Net income-1,218-302-374-362
Total adjustments to net income--------
Net income before extra. items-1,218-302-374-362
Minority interest12-11
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-1,218-302-374-362
Inc. avail. to common incl. extra. items-1,218-302-374-362
Diluted net income-1,218-302-374-362
Dilution adjustment--0----
Diluted weighted average shares350345345348
Diluted EPS excluding extraordinary itemsvalue per share-3.49-0.88-1.08-1.04
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-1.38-0.78-1.00-0.54